DOYLESTOWN, Pa., Sept. 11 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY - News) today issued an update on a Phase IIb Clinical Study of QR-333 on Diabetic Peripheral Neuropathy by its wholly owned subsidiary, Quigley Pharma, www.QuigleyPharma.com.
